December 21, 2017 / 6:32 PM / a year ago

BRIEF-FDA grants second breakthrough therapy designation for Avelumab in hard-to-treat cancer​

Dec 21 (Reuters) - Merck Kgaa:

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA

* SAYS ‍SECOND BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN HARD-TO-TREAT CANCER​

* SAYS ‍RENAL CELL CARCINOMA, MOST COMMON FORM OF KIDNEY CANCER, HAS A POOR PROGNOSIS IN ADVANCED STAGE​

* SAYS ‍JAVELIN RENAL CLINICAL DEVELOPMENT PROGRAM IS ONGOING, INCLUDING PHASE III FIRST-LINE STUDY​

* SAYS ‍FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA(®) (AXITINIB)* FOR TREATMENT-NAÏVE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA​ Source text for Eikon: Further company coverage: (Frankfurt newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below